| Detected | Trial | Change |
|---|---|---|
| 2026-05-21 | NCT06597734 A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in… |
overall status: "Recruiting" → "Withdrawn" |
| 2026-05-21 | NCT06597734 A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in… |
critical why stopped: null → "PI request" |
| 2026-05-21 | NCT06597734 A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in… |
Enrollment reduced: 45 -> 0 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-22 | NCT07604064 A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia | Phase 2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | AML (Acute Myeloid Leukemia) | Recruiting |
| Phase 2 | |||
| NCT06566742 | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of… | Myelodysplastic Syndromes | Recruiting |
| NCT06668584 | A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for… | Myeloid Malignancies | Recruiting |
| NCT07304011 | Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of… | Acute Myeloid Leukemia | Recruiting |
| NCT07032727 | Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated… | Targeted Therapy | Recruiting |
| NCT06782542 | Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid… | Acute Myeloid Leukemia | Recruiting |
| NCT07604064 | A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia | Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia | Recruiting |
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study… | Acute Myeloid Leukemia | Recruiting |
| NCT07153497 | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to… | Acute Myeloid Leukemia | Not Yet Recruiting |
| NCT07471841 | Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax | IDH1 Mutation | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06445959 | Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant… | Mutant IDH1 Inhibitor Olutasidenib | Recruiting |
| Phase 1 | |||
| NCT06543381 | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor… | Acute Myeloid Leukemia | Recruiting |
| NCT07411586 | Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute… | Acute Myeloid Leukemia | Not Yet Recruiting |